Smith, Moore & Co. Gilead Sciences, Inc. Transaction History
Smith, Moore & Co.
- $935 Million
- Q1 2024
A detailed history of Smith, Moore & Co. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Smith, Moore & Co. holds 3,121 shares of GILD stock, worth $213,476. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,121
Previous 2,906
7.4%
Holding current value
$213,476
Previous $235,000
2.98%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding GILD
# of Institutions
1,885Shares Held
1BCall Options Held
8.71MPut Options Held
8.02M-
Black Rock Inc. New York, NY123MShares$8.38 Billion0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$7.85 Billion0.17% of portfolio
-
Capital World Investors Los Angeles, CA84.5MShares$5.78 Billion1.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.2MShares$4.19 Billion1.05% of portfolio
-
State Street Corp Boston, MA57.7MShares$3.95 Billion0.19% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $85.7B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...